News Releases

Year

13 Apr '21

Repare Therapeutics to Present at the 2021 Bloom Burton & Co. Virtual Healthcare Investor Conference

CAMBRIDGE, Mass. & MONTREAL, Quebec --(BUSINESS WIRE)--Apr. 13, 2021-- Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel

08 Apr '21

Repare Therapeutics to Highlight Program Progress for RP-6306 at Today’s Virtual Investor Day Event

-Company highlights pre-clinical anti-tumor activity of RP-6306 , a first-in-class, selective, oral inhibitor of PKMYT1, which is synthetic lethal with CCNE1 amplification and other genomic mutations- - Initiation of Phase 1 clinical trial enrollment for RP-6306 anticipated to begin during this

30 Mar '21

Repare Therapeutics to Introduce RP-6306, a Potent and Specific Inhibitor of a Novel Target, at Virtual Investor Day on April 8

CAMBRIDGE, Mass. & MONTREAL --(BUSINESS WIRE)--Mar. 30, 2021-- Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics,

29 Mar '21

Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans

CAMBRIDGE, Mass. & MONTREAL --(BUSINESS WIRE)--Mar. 29, 2021-- Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics,

04 Mar '21

Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

Initiated patient recruitment of PARP-inhibitor combination arm of RP-3500 TRESR Phase 1/2 clinical trial Initiated IND-enabling studies for RP-6306 , the Company’s CCNE-1 synthetic-lethal inhibitor program Phase 1 clinical trial for RP-6306 is anticipated to commence in 2Q 2021, reflecting a

23 Feb '21

Repare Therapeutics Announces March 2021 Virtual Investor Conference Participation

CAMBRIDGE, Mass. & MONTREAL --(BUSINESS WIRE)--Feb. 23, 2021-- Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics,

04 Jan '21

Repare Therapeutics to Present at Virtual Investor Conferences in January

CAMBRIDGE, Mass. & MONTREAL --(BUSINESS WIRE)--Jan. 4, 2021-- Repare Therapeutics, Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics,

Pagination

First page
Previous page
Page 1
Current page 2

Displaying 11 - 17 of 17